The temporal association of hyperhidrosis and its comorbidities – a nationwide hospital-based cohort study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Dokumenter

  • Fulltext

    Forlagets udgivne version, 1,26 MB, PDF-dokument

Background: Research on hyperhidrosis comorbidities has documented the co-occurrence of diseases but has not provided information about temporal disease associations. Objective: To investigate the temporal disease trajectories of individuals with hospital-diagnosed hyperhidrosis. Methods: This is a hospital-based nationwide cohort study including all patients with a hospital contact in Denmark between 1994 and 2018. International Classification of Diseases version-10 diagnoses assigned to inpatients, outpatients and emergency department patients were collected from the Danish National Patient Register. The main outcome was the temporal disease associations occurring in individuals with hyperhidrosis, which was assessed by identifying morbidities significantly associated with hyperhidrosis and then examining whether there was a significant order of these diagnoses using binomial tests. Results: Overall, 7 191 519 patients were included. Of these, 8758 (0.12%) patients had localized hyperhidrosis (5674 female sex [64.8%]; median age at first diagnosis 26.9 [interquartile range 21.3–36.1]) and 1102 (0.015%) generalized hyperhidrosis (606 female sex [59.9%]; median age at first diagnosis 40.9 [interquartile range 26.4–60.7]). The disease trajectories comprised pain complaints, stress, epilepsy, respiratory and psychiatric diseases. The most diagnosed morbidities for localized hyperhidrosis were abdominal pain (relative risk [RR] = 121.75; 95% Confidence Interval [CI] 121.14–122.35; P < 0.001), soft tissue disorders (RR = 151.19; 95% CI 149.58–152.80; P < 0.001) and dorsalgia (RR = 160.15; 95% CI 158.92–161.38; P < 0.001). The most diagnosed morbidities for generalized hyperhidrosis were dorsalgia (RR = 306.59; 95% CI 302.17–311.02; P < 0.001), angina pectoris (RR = 411.69; 95% CI 402.23–421.16; P < 0.001) and depression (RR = 207.92; 95% CI 202.21–213.62; P < 0.001). All these morbidities were diagnosed before hyperhidrosis. Conclusions: This paper ascertains which hospital-diagnosed morbidities precede hospital-diagnosed hyperhidrosis. As hyperhidrosis mainly is treated in the primary health care sector, the trajectories suggests that these morbidities may lead to a worse disease course of hyperhidrosis that necessitates treatment in hospitals. Treating these morbidities may improve the disease course of hyperhidrosis.

OriginalsprogEngelsk
TidsskriftJournal of the European Academy of Dermatology and Venereology
Vol/bind36
Udgave nummer12
Sider (fra-til)2504-2511
ISSN0926-9959
DOI
StatusUdgivet - 2022

Bibliografisk note

Funding Information:
Mattias AS Henning and Rune Kjærsgaard Andersen report grants from Leo Foundation (grant number LF‐18002). Roc Reguant and Isabella Friis Jørgensen report grants from Novo Nordisk Foundation (the Core grant NNF14CC0001 and the Challenge grant NFF17OC0027594). Gregor B Jemec reports grants and personal fees from Abbvie, personal fees from Coloplast, personal fees from Chemocentryx, personal fees from LEO pharma, grants from LEO Foundation, grants from Afyx, personal fees from Incyte, grants and personal fees from InflaRx, grants from Janssen‐Cilag, grants and personal fees from Novartis, grants and personal fees from UCB, grants from CSL Behring, grants from Regeneron, grants from Sanofi, personal fees from Kymera, personal fees from VielaBio, outside the submitted work. Søren Brunak has ownerships in Intomics A/S, Hoba Therapeutics Aps, Novo Nordisk A/S, Lundbeck A/S and managing board membership in Intomics A/S. Kristina S Ibler reports personal fees from Leo Pharma, Sanofi Genzymes, Astra Zeneca and Eli Lilly. Ole B Pedersen has no conflicts of interest.

Funding Information:
Mattias Henning and Rune Kjærsgaard Andersen were provided research grants from Leo Foundation Denmark (grant number LF‐18002). Søren Brunak, Isabella Jørgensen and Roc Reguant were provided grants from the Novo Nordisk Foundation (the Core grant NNF14CC0001 and the Challenge grant NFF17OC0027594). No study sponsor or funder has taken part in the study design, data collection, data analysis or manuscript preparation.

Publisher Copyright:
© 2022 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

Antal downloads er baseret på statistik fra Google Scholar og www.ku.dk


Ingen data tilgængelig

ID: 314157820